Golgi Protein 73 and Laminin‐γ2 Monomer‐Based Score for the Diagnosis of Advanced Liver Fibrosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
Xin‐Tong Ng, Jin‐Ying Teh, Pavai Sthaneshwar, Izzatul Aliaa Badaruddin, Pavitratha Puspanathan, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah‐Kheong ChanABSTRACT
Background
This study evaluated the diagnostic performance of Golgi protein 73 (GP73), laminin‐γ2 monomer (LG2m), and the GLAS score in detecting advanced fibrosis in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD).
Methods
This study included patients with MASLD who underwent liver biopsy. The performance of serum levels of GP73 and LG2m and the GLAS score to diagnose advanced fibrosis was evaluated using area under receiver operating characteristic curves (AUROC).
Results
The data for 209 patients with MASLD were analyzed [median age 52 (42–58) years, 53.1% men, 71.3% had steatohepatitis, 18.1% had advanced fibrosis]. The serum levels of GP73 and LG2m and the GLAS score were significantly higher in patients with advanced fibrosis compared to patients without advanced fibrosis [GP73: 83 ± 50 ng/mL vs. 61 ± 35 ng/mL, p = 0.013; LG2m: 31 (14–48) pg/mL vs. 17 (12–23) pg/mL, p < 0.001; GLAS score: 0.89 (0.49–0.97) vs. 0.47 (0.15–0.78), p < 0.001]. The AUROC of serum levels of GP73 and LG2m and GLAS for diagnosing advanced fibrosis was 0.63 (0.52–0.74), 0.73 (0.62–0.83), and 0.72 (0.61–0.82), respectively. Using the optimal cut‐off of 27 pg/mL, the sensitivity, specificity, positive predictive value, and negative predictive value of LG2m for diagnosing advanced fibrosis were 60.5%, 86.0%, 48.9%, and 90.7%, respectively. Using the optimal cut‐off of 0.75, the corresponding values for the GLAS score were 65.8%, 73.7%, 35.7%, and 90.6%, respectively.
Conclusion
Serum LG2m level and the GLAS score have fair accuracy for the diagnosis of advanced fibrosis in patients with MASLD.